Pfizer launched China's first pay-for-performance model for oncology, according to a BioCentury news report. The model was launched for Pfizer's breast cancer drug, Ibrance.
Under the model, Pfizer will reimburse enrolled patients up to 33.5 percent of the Ibrance treatment cost if they metastasis within the first 126 days or experience disease progression after starting Ibrance in combination with an aromatase inhibitor.
To be eligible, this must be the first endocrine therapy patients have received, and they must enroll in the program within 28 days of beginning Ibrance.
The program will be capped at 500 patients.